MJ33 is a novel active site-directed, specific, competitive, and reversible inhibitor of phospholipase A2 (PLA2). MJ33 has inhibitory activity against a low pH calcium-independent PLA2 as well as against the PLA2 activity responsible for permeability barrier homeostasis or esophagitis.
